Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

NCT06858956 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences